1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Death knell sounds for CB1 antagonists

 
• By Alexandra Shimmings

Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. [C#198601345:Sanofi-Aventis] is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and [C#198600199:Pfizer]is discontinuing its Phase III candidate CP-945,598.

Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. Sanofi-Aventis is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and Pfizeris discontinuing its Phase III candidate CP-945,598.

Sanofi-Aventis's decision was prompted by French and German regulators wanting to stop ongoing trials of rimonabant because of safety concerns

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.